ISSN: 1533-0028

Journal Home

Journal Guideline

Clinical Colorectal Cancer Q1 Unclaimed

Elsevier Inc. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Clinical Colorectal Cancer is a journal indexed in SJR in Oncology and Gastroenterology with an H index of 63. It has an SJR impact factor of 1,336 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,336.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Gastroenterology (Q1) Oncology (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,336

SJR Impact factor

63

H Index

57

Total Docs (Last Year)

232

Total Docs (3 years)

2324

Total Refs

637

Total Cites (3 years)

211

Citable Docs (3 years)

2.97

Cites/Doc (2 years)

40.77

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Molecular Cancer Q1
Journal of Thoracic Oncology Q1
JAMA oncology Q1
Cancer Discovery Q1
Journal of Hematology and Oncology Q1

Compare this journals

Aims and Scope

Best articles by citations

Predictive Value of Early Tumor Shrinkage and Density Reduction of Lung Metastases in Patients With Metastatic Colorectal Cancer Treated With Regorafenib

Prognostic Value of the Microsatellite Instability Status in Patients With Stage II/III Rectal Cancer Following Upfront Surgery

Quality of Life After Sphincter-Preserving Rectal Cancer Resection

Gene Expression Profiles as Predictors of Poor Outcomes in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis

The Role of Cyclooxygenase-2 in Colorectal Carcinogenesis

Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine

Capecitabine Combinations in the Treatment of Advanced Colorectal Cancer

Systemic Inflammatory Response Predicts Prognosis in Patients with Advanced-Stage Colorectal Cancer

Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study

Hepatic Arterial Infusion of 5-Fluorouracil for Patients With Liver Metastases From Colorectal Cancer Refractory to Standard Systemic Chemotherapy: A Multicenter, Retrospective Analysis

37th Annual Meeting of the American Society of Clinical Oncology; San Francisco, CA May 12-15, 2001

Integrating Targeted Agents into Therapeutic Regimens for Patients with Resectable Colorectal Cancer

SHOW MORE ARTICLES

Factors Predicting Adherence to a Tailored-Dose Adjuvant Treatment on the Basis of Geriatric Assessment in Elderly People With Colorectal Cancer: A Prospective Study

25th European Society for Medical Oncology Congress; Hamburg, Germany October 13-17, 2000

Recommendation for Irinotecan, 5-Fluorouracil, and Leucovorin as First-Line Therapy for Colorectal Cancer

Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases

Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer

Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions

Incidence of Chemotherapy- and Chemoradiotherapy-Induced Amenorrhea in Premenopausal Women With Stage II/III Colorectal Cancer

Safety and Efficacy of Panitumumab Therapy After Progression With Cetuximab: Experience at Two Institutions

Equal Opportunity for the Elderly

Updated Options for Liver-Limited Metastatic Colorectal Cancer

Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer

Management of Rash and Other Toxicities in Patients Treated with Epidermal Growth Factor Recep tor-Targeted Agents